Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianlie Xiaozhuo Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by the Shunyi Hospital of Traditional Chinese Medicine for the treatment of type III chronic prostatitis (chronic pelvic pain syndrome). It is specifically indicated for adult male patients exhibiting the TCM syndrome of damp-heat and blood stasis. The formula is hypothesized to exert its therapeutic effects by modulating peripheral blood immune cell heterogeneity and inflammatory responses. In clinical research, its efficacy is being evaluated in comparison to tamsulosin hydrochloride sustained-release capsules, with studies utilizing patient-reported symptom scores, routine laboratory tests, and single-cell RNA sequencing of immune cells to elucidate its impact on the systemic immune landscape.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qianlie xiaozhuo formula.